2月26日,复星医药(600196/02196)发布公告,控股子公司重庆药友制药有限责任公司就盐酸溴己新注射液的药品注册申请于近日获国家药品监督管理局受理。该药品为公司自主研发的化学药品,拟用于在口服给药困难的情况下治疗肺结核、尘肺病及手术后的祛痰。截至2025年1月,公司针对盐酸溴己新注射液的累计研发投入约为164万元。根据IQVIACHPA的最新数据,2023年盐酸溴己新注射剂在中国境内的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.